Maitra P, Prema S, Narendran V, Shah PK. Safety and efficacy of intravitreal anti vascular endothelial growth factor for severe posterior retinopathy of prematurity with flat fibrovascular proliferation. World J Clin Pediatr 2023; 12(4): 220-229 [PMID: 37753496 DOI: 10.5409/wjcp.v12.i4.220]
Corresponding Author of This Article
Parag K Shah, DNB, Professor, Pediatric Retina & Ocular Oncology, Aravind Eye Hospital, Avinashi Road, Coimbatore 641014, Tamil Nadu, India. drshahpk2002@yahoo.com
Research Domain of This Article
Ophthalmology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Pediatr. Sep 9, 2023; 12(4): 220-229 Published online Sep 9, 2023. doi: 10.5409/wjcp.v12.i4.220
Safety and efficacy of intravitreal anti vascular endothelial growth factor for severe posterior retinopathy of prematurity with flat fibrovascular proliferation
Puja Maitra, Subramaniam Prema, Venkatapathy Narendran, Parag K Shah
Puja Maitra, Subramaniam Prema, Venkatapathy Narendran, Parag K Shah, Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore 641014, Tamil Nadu, India
Author contributions: Shah PK and Narendran V designed the research study; Maitra P and Prema S performed the research; Narendran V contributed towards analytic tools; Maitra P, Prema S and Shah PK analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Aravind Eye Hospital Institutional Ethics Committee (Approval No. RET201300423).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at email address: drshahpk2002@yahoo.com. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Parag K Shah, DNB, Professor, Pediatric Retina & Ocular Oncology, Aravind Eye Hospital, Avinashi Road, Coimbatore 641014, Tamil Nadu, India. drshahpk2002@yahoo.com
Received: May 5, 2023 Peer-review started: May 5, 2023 First decision: June 19, 2023 Revised: June 26, 2023 Accepted: July 7, 2023 Article in press: July 7, 2023 Published online: September 9, 2023 Processing time: 123 Days and 16.3 Hours
ARTICLE HIGHLIGHTS
Research background
There is always a dilemma whether or not intravitreal anti-vascular endothelial growth factor (IVA) injections can be given in severe retinopathy of prematurity (ROP) with fibro vascular proliferation (FVP).
Research motivation
The outcome of laser alone in treating severe posterior ROP with FVP is poor. Hence we wanted to test if IVA injections could be a better option for these subset of cases.
Research objectives
To test if early IVA injections in severe posterior ROP with FVP would cause worsening of the disease.
Research methods
It is a retrospective study which included 36 eyes of 18 babies, which were given IVA injections for severe posterior ROP with FVP and followed up till 5 years of age.
Research results
There was no contraction of the FVP in any of the eyes after the IVA injections. All eyes showed very good regression. The mean post menstrual age of injection was 35.5 wk. Five eyes showed disease reactivation on follow up which was treated by laser in 3 eyes and repeat IVA injections in 2 eyes.
Research conclusions
IVA injections can be tried as an initial treatment in severe posterior ROP with FVP, if the post menstrual age at the time if injection is < 37 wk.
Research perspectives
IVA injections could be used as a first line treatment in the management of severe posterior ROP with FVP.
